AbbVie to buy Pharmacyclics for US$21b
Print Edition
ABBVIE Inc is to buy Pharmacyclics Inc for about US$21 billion, giving it access to what is expected to be one of the world’s top-selling cancer drugs and expanding its reach in the profitable oncology field.
The deal — the latest example of a big drugmaker swooping on a biotech firm to refill its medicine pipeline — confounds expectations that Pharmacyclics would sell out to Johnson & Johnson.
AbbVie will pay US$261.25 per share in cash and stock, a 13 percent premium to Pharmacyclics stock’s closing price on Wednesday. Back in 2008 and 2009, the shares dipped below US$1.
The acquisition lessens Chicago-based AbbVie’s dependence on its blockbuster rheumatoid arthritis drug Humira that accounts for most of its revenue but is expected to start to see sales decline from 2017 or 2018.
AbbVie failed last October to buy Dublin-based Shire Plc for US$55 billion after the United States took steps to deter such tax-lowering deals.
Deutsche Bank analyst Robyn Karnauskas said the deal was positive for AbbVie as Pharmacyclics’ blood cancer treatment Imbruvica would diversify the business beyond Humira.
“Imbruvica is not only complementary to AbbVie’s oncology pipeline, it has demonstrated strong clinical efficacy across a broad range of hematologic malignancies,” AbbVie Chief Executive Richard Gonzalez said in a statement.
Pharmacyclics expects US sales of Imbruvica to hit US$1 billion this year and by 2020 worldwide sales are forecast to reach US$5.8 billion, according to consensus analyst estimates compiled by Thomson Reuters Cortellis.
AbbVie, which was spun out of Abbott Laboratories in 2013, said the deal would be “highly accretive” to its revenue and earnings by 2017.
Sunnyvale, California-based Pharmacyclics co-markets Imbruvica with Johnson & Johnson. Besides Imbruvica, it has three product candidates in development.
Media reports had said J&J was close to buying Pharmacyclics.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 娌狪CP璇侊細娌狪CP澶05050403鍙-1
- |
- 浜掕仈缃戞柊闂讳俊鎭湇鍔¤鍙瘉锛31120180004
- |
- 缃戠粶瑙嗗惉璁稿彲璇侊細0909346
- |
- 骞挎挱鐢佃鑺傜洰鍒朵綔璁稿彲璇侊細娌瓧绗354鍙
- |
- 澧炲肩數淇′笟鍔＄粡钀ヨ鍙瘉锛氭勃B2-20120012
Copyright 漏 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
